Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease

Movement Disorders

Volumn 25, Issue 8, 2010, Pages 1091-1096

  Li, Jia Yi ^a   Englund, Elisabet ^b   Widner, Håkan ^b   Rehncrona, Stig ^b   Björklund, Anders ^a   Lindvall, Olle ^a,b   Brundin, Patrik ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Lewy body; Neural transplantation; Protein aggregation; Transmissible neurological disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; THIOFLAVINE; UBIQUITIN; THIAZOLE DERIVATIVE;

ADOLESCENT; ARTICLE; BRAIN GRAFT; BRAIN NERVE CELL; CASE REPORT; CHILD; DEATH; DOPAMINERGIC NERVE CELL; ELECTRON MICROSCOPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRASTRIATAL MESENCEPHALIC GRAFT; LEWY BODY; MALE; PARKINSON DISEASE; PATHOLOGY; PRIORITY JOURNAL; PUTAMEN; SCHOOL CHILD; SUBSTANTIA NIGRA; SURVIVAL; CYTOLOGY; DIAGNOSTIC USE; FETAL TISSUE TRANSPLANTATION; LONGITUDINAL STUDY; MESENCEPHALON; METABOLISM; MIDDLE AGED; NERVE CELL; POSTMORTEM CHANGE; PROCEDURES; TIME; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ALPHA-SYNUCLEIN; FETAL TISSUE TRANSPLANTATION; HUMANS; LEWY BODIES; LONGITUDINAL STUDIES; MALE; MESENCEPHALON; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; NEURONS; PARKINSON DISEASE; POSTMORTEM CHANGES; THIAZOLES; TIME FACTORS;

EID: 77949820437     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23012     Document Type: Article

References (24)

1. Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol 2001;60:741-752.
2. Lindvall O, Björklund A. Cell therapy in Parkinson's disease. NeuroRx 2004;1:382-393.
3. Piccini P, Brooks DJ, Björklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999;2:1137-1140. (Pubitemid 30126374)
4. Mendez I, Sanchez-Pernaute R, Cooper O, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005;128:1498-1510. (Pubitemid 41373670)
5. Kordower JH, Freeman TB, Chen EY, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 1998;13:383-393.
6. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-1124.
7. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;14:501-503.
8. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14:504-506. (Pubitemid 351655212)
9. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 2008;23:2303-2306.
10. Hagell P, Schrag A, Piccini P, et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 1999;122:1121-1132. (Pubitemid 29533127)
11. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990;247:574-577. (Pubitemid 20073682)
12. Double KL, Dedov VN, Fedorow H, et al. The comparative biology of neuromelanin and lipofuscin in the human brain. Cell Mol Life Sci 2008;65:1669-1682.
13. Greffard S, Verny M, Bonnet AM, Seilhean D, Hauw JJ, Duyckaerts C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol Aging 2010;31:99-103.
14. Olanow CW, Perl DP, Demartino GN, Mcnaught KS. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004;3:496-503.
15. Alafuzoff I, Ince PG, Arzberger T, et al. Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 2009;117:635-652.
16. Li JY, Henning Jensen P, Dahlstrom A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neuroscience 2002;113:463-478.
17. Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol Dis 2007;25:134-149.
18. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci 2008;9:741-745.
19. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 2009;106:13010-13015.
20. Aguzzi A. Cell biology: beyond the prion principle. Nature 2009;459:924-925.
21. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009;284:12845-12852.
22. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009;11:219-225.
23. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009;11:909-913.
24. Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211. (Pubitemid 36007810)